Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 11, 2011, Pages 1549-1560

  Rebello, Sam ^a   Compain, Séverine ^a   Feng, Aimin ^a   Hariry, Sam ^a   Dieterich, Hans Armin ^b   Jarugula, Venkateswar ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Galenus GH AG   (Switzerland)

Author keywords

Aliskiren; cyclosporine; efflux transporter; MDR1 transporter; multidrug resistance transporter 1

Indexed keywords

ALISKIREN; CYCLOSPORIN; CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIGAMENT RUPTURE; MALE; NAUSEA; NERVOUSNESS; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AMIDES; AREA UNDER CURVE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; FUMARATES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; YOUNG ADULT;

EID: 80054729063     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010385934     Document Type: Article

References (30)

1. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 ; 308: 698-705 (Pubitemid 36976519)
2. Tekturna package insert. http://www.rxlist.com/tekturna-drug.htm. August 31, 2010.
3. Rasilez Summary of Product Characteristics. European Medicines Agency. http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm. August 31, 2010.
4. Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe D. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 ; 49: 1157-1163 (Pubitemid 46400330)
5. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226 (Pubitemid 44885684)
6. Kilo C, Taylor A, Tschoepe D, Ibram G, Fang H, Prescott MF. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 ; 8: 190-198 (Pubitemid 351166266)
7. Azizi M, Menard J, Bissery A, Guyene T, Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007 ; 2: 947-955
8. Vaidyanathan S, Jarugula V, Dieterich HA, Howard1 D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008 ; 47: 515-531 (Pubitemid 351969826)
9. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008 ; 48: 1323-1338
10. Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol. 2010 ;:
11. Tapaninen T, Backman J, Kurkinen K, Neuvonen P, Niemi M. Itraconazole, a P-glycoprotein and CYP3A4 Inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol. 2010 ;:
12. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007 ; 35: 1418-1428 (Pubitemid 47121784)
13. Koseki N, Nakashima A, Nagae Y, Masuda N. Simultaneous quantitative determination of cyclosporine A and its three main metabolites (AM1, AM4N and AM9) in human blood by liquid chromatography/mass spectrometry using a rapid sample processing method. Rapid Commun Mass Spectrom. 2006 ; 20: 733-740 (Pubitemid 43326677)
14. Guidance for Industry, Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Silver Spring, Md: FDA ; 2006 :
15. Kajosaari L, Niemi M, Neuvonen M, Laitila J, Neuvonen P, Backman J. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005 ; 78: 388-399 (Pubitemid 41393674)
16. Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol. 2008 ; 48: 799-811 (Pubitemid 351871965)
17. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1996 ; 59: 297-303 (Pubitemid 26122201)
18. Larsen UL, Olesen HL, Guldborg NC, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007 ; 67: 123-134 (Pubitemid 46410602)
19. Terwogt JM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999 ; 5: 3379-3384
20. Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003 ; 73: 223-231 (Pubitemid 36269673)
21. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 (OATP1B1) is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 ; 77: 468-478 (Pubitemid 40824960)
22. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002 ; 40: 439-450
23. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther. 2004 ; 75: 101-109 (Pubitemid 38130122)
24. Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008 ; 46: 252-258 (Pubitemid 351663162)
25. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens. 2006 ; 24: 243-256 (Pubitemid 43348229)
26. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy. 1993 ; 13: 613-617 (Pubitemid 23347034)
27. Kovarik JM, Barilla D, McMahon L, Wang Y, Kisicki J, Schmouder R. Administration diluents differentiate Neoral from a generic cyclosporine oral solution. Clin Transplant. 2002 ; 16: 306-309 (Pubitemid 34830849)
28. Kees F, Mair G, Dittmar M, Bucher M. Cicloral versus Neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. Transplant Proc. 2004 ; 36: 3234-3238 (Pubitemid 41126782)
29. Bergman AJ, Burke J, Larson P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006 ; 46: 321-327 (Pubitemid 43260319)
30. Kees F, Bucher M, Schweda F, Gschaidmeier H, Faerber L, Seifert R. Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun. Naunyn Schmiedebergs Arch Pharmacol. 2007 ; 375: 393-399 (Pubitemid 47087495)